Developer docs
API playgroundTry for free, no card

Search company profiles

HepQuant

Full company profile

uuid0008qqm

Namestring
HepQuant
Legal namestring
HepQuant, LLC
Websiteurl
hepquant.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

HepQuant is a privately held clinical diagnostics company that develops noninvasive, blood-based quantitative tests for liver function assessment. Founded in 2007 by Dr. Gregory T. Everson (formerly Professor of Medicine and Director of Hepatology at the University of Colorado), the company is headquartered in Denver, Colorado with a CAP-accredited, CLIA-certified analytical laboratory at the Fitzsimons Innovation Community Campus in Aurora, adjacent to the University of Colorado Anschutz Medical Campus. Its core technology, the oral cholate challenge test (OCCT) combined with intravenous 13C-cholate clearance, directly measures hepatocyte function and portal blood inflow using LC-MS-based blood assays, producing a quantitative Disease Severity Index (DSI), SHUNT% (portal-systemic shunting), Hepatic Reserve, and a Risk for Adverse Clinical Events (RISK ACE) score.

HepQuant's commercial product portfolio comprises two principal offerings. The HepQuant SHUNT Liver Diagnostic Test received FDA premarket approval in June 2026 and is the only FDA-approved blood-based test for quantifying risk of large esophageal varices in adult patients with compensated cirrhosis (Child-Pugh Class A), demonstrated at 100% sensitivity and 100% negative predictive value in the SHUNT-V pivotal study (n=195). The HepQuant DuO is a Laboratory Developed Test (LDT) analyzed in-house, providing broader quantitative liver function and disease severity assessment, and is the primary product used in the company's Early Access Program for hepatologists and gastroenterologists. A Pharma Solutions module extends testing into clinical trial services, with named engagements including Madrigal Pharmaceuticals' Phase 3 MAESTRO-NAFLD-1 trial of resmetirom in MASH cirrhosis and Hepion Pharmaceuticals' Phase 2 ALTITUDE-NASH trial, plus a pilot with eGenesis on genetically modified porcine liver and research with the University of Pennsylvania on extracorporeal liver support.

HepQuant generates revenue primarily through two streams: (1) clinical diagnostic testing fees from healthcare providers ordering the HepQuant DuO and SHUNT tests (processed at its in-house lab), and (2) clinical trial testing services for pharmaceutical companies, with test costs flowing through standard laboratory billing and reimbursement. The company has historically funded operations through Colorado state grants (OEDIT Advanced Industry Accelerator Grant Program), University of Colorado research funding, and founder/backer capital (with President Randy Dietrich identified as a major financial backer since founding); no institutional venture capital rounds are disclosed. Commercial go-to-market relies on direct sales, a Chief Commercial Officer and regional Key Account Managers, and an event-driven presence at major hepatology conferences (AASLD, EASL, DDW, MASH-TAG).

Short descriptiontext

HepQuant develops noninvasive, blood-based quantitative liver function diagnostics using oral cholate clearance methodology. Its FDA-approved HepQuant SHUNT test and HepQuant DuO Laboratory Developed Test serve hepatologists, gastroenterologists, and pharmaceutical companies running liver disease clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDenver, United States
HQ citystring
Denver
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liver function diagnostics, quantitative liver testing, noninvasive liver assessment, clinical trial endpoints, esophageal varices screening
Industry4 codes
PRIMARYHLAKAEAB
Hepatology & Liver Disease
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAE
Clinical Chemistry, Hematology & Coagulation Testing (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories
NAICS code3 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Liver Disease Diagnostics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Diagnostic Testing Services
TypeSubscription Recurring
Description

HepQuant DuO is a Laboratory Developed Test (LDT) analyzed at the company's CAP-accredited, CLIA-certified laboratory. Healthcare providers submit patient samples for quantitative liver function assessment. Revenue is generated through test processing fees.

hepquant.com
2Pharma Solutions / Clinical Trial Testing
TypeProfessional Services
Description

Provides quantitative liver function testing services to pharmaceutical companies conducting clinical trials in liver disease. Includes support for Phase 2 and 3 drug trials, with HepQuant's tests used as endpoints for assessing treatment efficacy and patient stratification.

hepquant.com
3Grant Funding
TypeLicensing Royalties
Description

Received state-sponsored funding through Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industry Accelerator Grant Program for supply chain development, regulatory advancements, and laboratory establishment.

hepquant.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Laboratory Developed Test - No public pricing available
ModelOtherBilling cadencePay-as-you-go
Notes

Test is not priced publicly; operates through laboratory services model with healthcare provider ordering and standard clinical billing/reimbursement processes.

hepquant.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1HepQuant DuO
Description

A noninvasive, blood-based quantitative test that measures liver function and portal circulation through a Disease Severity Index (DSI) score. It assesses critical liver cell processes and blood flow to the liver.

hepquant.com
+1 more record
Core offering1 text field

HepQuant develops and provides noninvasive, blood-based quantitative liver function tests analyzed at its own CAP-accredited, CLIA-certified laboratory. Its core offerings are the FDA PMA-approved HepQuant SHUNT test for identifying patients with compensated cirrhosis unlikely to have large esophageal varices, and the HepQuant DuO Laboratory Developed Test that delivers a Disease Severity Index (DSI) along with portal-systemic shunting and hepatic reserve metrics. The company also supplies quantitative liver endpoints to pharmaceutical sponsors for use in liver disease clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% sensitivity and 100% negative predictive value for identifying patients unlikely to have large esophageal varices at DSI threshold of 18.3
+4 more records
Product overview1 text field

HepQuant offers a portfolio of noninvasive, blood-based, quantitative liver function tests. The core offerings are the FDA-approved HepQuant SHUNT® Liver Diagnostic Test and the HepQuant DuO® Laboratory Developed Test (LDT). The SHUNT test received FDA premarket approval in June 2026 for identifying patients unlikely to have large esophageal varices, while the HepQuant DuO test provides broader liver health assessment including Disease Severity Index (DSI), SHUNT%, Hepatic Reserve (HR%), and Risk for Adverse Clinical Events (RISK ACE) metrics. The Pharma Solutions module extends these tests for use in pharmaceutical clinical trials, enabling drug developers to assess liver function and physiology across various liver disease presentations.

Product and service2 records
1HepQuant SHUNT Liver Diagnostic Test
CategoryLiver Disease Diagnostics
Description

FDA PMA-approved blood-based liver diagnostic test that generates a Disease Severity Index (DSI) score to identify adult patients with compensated cirrhosis (Child-Pugh Class A) unlikely to have large esophageal varices, potentially sparing them from endoscopy. It measures clearances of intravenously and orally administered cholate to assess liver function and portal-systemic shunting.

2HepQuant DuO
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

One of the largest US clinical reference laboratories operating CAP/CLIA labs nationwide with a broad hepatology and MASH testing menu. Relevant as both a potential commercial channel partner and a broad incumbent competing for clinical-trial central lab business against HepQuant's pharma services.

TypeBroad incumbent
Description

Offers the ADVIA Centaur ELF (Enhanced Liver Fibrosis) test on its clinical chemistry immunoassay platforms, a widely deployed noninvasive liver fibrosis assessment. Comparable as an incumbent blood-based liver fibrosis diagnostic competing for hepatology adoption.

TypeDirect peer
Description

Developer of NIS4, a blood-based MASH diagnostic biomarker test commercialized in the US through Labcorp. Targets the same hepatology/MASH patient stratification use case and pharma clinical-trial endpoint positioning as HepQuant.

TypeOthers
Description

Commercial-stage blood-based screening diagnostics company (Cologuard, Oncotype) with a large direct sales force targeting clinicians. Comparable as a US commercial-stage diagnostics platform whose playbook (CCO alumni at HepQuant helped build) and direct-to-physician model HepQuant is replicating for hepatology.

TypeDirect peer
Description

Developer of LiverMultiScan, an MR-based quantitative liver diagnostic used for liver disease assessment and clinical-trial endpoints in MASH/NASH. Directly comparable to HepQuant as a quantitative, noninvasive liver diagnostic targeting hepatologists and pharma sponsors.

TypeBroad incumbent
Description

Global clinical laboratory network with significant hepatology and gastroenterology testing services across the US, Europe, and Australia. Comparable as a broad incumbent that could partner with or compete against HepQuant for clinical-trial central lab and specialty liver testing volume.

7Echosens
TypeDirect peer
Description

Commercial-stage developer of FibroScan, the dominant noninvasive point-of-care liver elastography device used by hepatologists worldwide. Directly competes with HepQuant for the same hepatology customer segment seeking noninvasive liver disease assessment.

TypeBroad incumbent
Description

Life-science tools and diagnostics company with proprietary biomarker assay content (including exosome-based and proteomic platforms) sold into pharma clinical trials and research labs. Comparable as a broader biomarker and clinical-trial assay supplier overlapping with HepQuant's pharma-services positioning.

TypeBroad incumbent
Description

Major US clinical reference laboratory with broad liver disease testing panels and clinical-trial central lab services. Comparable as a large incumbent serving hepatology providers and pharma sponsors across many of the same use cases HepQuant targets.

TypeEmerging player
Description

Privately held blood-based diagnostics company with proprietary mass-spec-based assays and a CLIA-certified lab, known for the PrecivityAD Alzheimer's test. Comparable as an emerging specialty blood-based diagnostics company with a CAP/CLIA lab and pharma-services exposure, though focused on neurology rather than hepatology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HepQuant

Liver Disease Diagnosticshepquant.com

HepQuant develops noninvasive, blood-based quantitative liver function diagnostics using oral cholate clearance methodology. Its FDA-approved HepQuant SHUNT test and HepQuant DuO Laboratory Developed Test serve hepatologists, gastroenterologists, and pharmaceutical companies running liver disease clinical trials.

What HepQuant does

HepQuant is a privately held clinical diagnostics company that develops noninvasive, blood-based quantitative tests for liver function assessment. Founded in 2007 by Dr. Gregory T. Everson (formerly Professor of Medicine and Director of Hepatology at the University of Colorado), the company is headquartered in Denver, Colorado with a CAP-accredited, CLIA-certified analytical laboratory at the Fitzsimons Innovation Community Campus in Aurora, adjacent to the University of Colorado Anschutz Medical Campus. Its core technology, the oral cholate challenge test (OCCT) combined with intravenous 13C-cholate clearance, directly measures hepatocyte function and portal blood inflow using LC-MS-based blood assays, producing a quantitative Disease Severity Index (DSI), SHUNT% (portal-systemic shunting), Hepatic Reserve, and a Risk for Adverse Clinical Events (RISK ACE) score.

HepQuant's commercial product portfolio comprises two principal offerings. The HepQuant SHUNT Liver Diagnostic Test received FDA premarket approval in June 2026 and is the only FDA-approved blood-based test for quantifying risk of large esophageal varices in adult patients with compensated cirrhosis (Child-Pugh Class A), demonstrated at 100% sensitivity and 100% negative predictive value in the SHUNT-V pivotal study (n=195). The HepQuant DuO is a Laboratory Developed Test (LDT) analyzed in-house, providing broader quantitative liver function and disease severity assessment, and is the primary product used in the company's Early Access Program for hepatologists and gastroenterologists. A Pharma Solutions module extends testing into clinical trial services, with named engagements including Madrigal Pharmaceuticals' Phase 3 MAESTRO-NAFLD-1 trial of resmetirom in MASH cirrhosis and Hepion Pharmaceuticals' Phase 2 ALTITUDE-NASH trial, plus a pilot with eGenesis on genetically modified porcine liver and research with the University of Pennsylvania on extracorporeal liver support.

HepQuant generates revenue primarily through two streams: (1) clinical diagnostic testing fees from healthcare providers ordering the HepQuant DuO and SHUNT tests (processed at its in-house lab), and (2) clinical trial testing services for pharmaceutical companies, with test costs flowing through standard laboratory billing and reimbursement. The company has historically funded operations through Colorado state grants (OEDIT Advanced Industry Accelerator Grant Program), University of Colorado research funding, and founder/backer capital (with President Randy Dietrich identified as a major financial backer since founding); no institutional venture capital rounds are disclosed. Commercial go-to-market relies on direct sales, a Chief Commercial Officer and regional Key Account Managers, and an event-driven presence at major hepatology conferences (AASLD, EASL, DDW, MASH-TAG).

HepQuant firmographics

Firmographics
Name
HepQuant
Legal name
HepQuant, LLC
Website
https://hepquant.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
HepQuant develops noninvasive, blood-based quantitative liver function diagnostics using oral cholate clearance methodology. Its FDA-approved HepQuant SHUNT test and HepQuant DuO Laboratory Developed Test serve hepatologists, gastroenterologists, and pharmaceutical companies running liver disease clinical trials.
Ownership category
akta.pro rank

HepQuant industry classification

Industry
Product category
Liver Disease Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAKAEAB
Hepatology & Liver Disease
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAE
Clinical Chemistry, Hematology & Coagulation Testing (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAFAMAB
Clinical Chemistry & Immunoassay Laboratories

Keywords

  • Liver function diagnostics
  • Quantitative liver testing
  • Noninvasive liver assessment
  • Clinical trial endpoints
  • Esophageal varices screening

Where HepQuant is headquartered

Location

Headquarters

HQ city
Denver
HQ country
United States
HQ region
North America

Offices2 records

Markets served

HepQuant business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Clinical Diagnostic Testing Services: HepQuant DuO is a Laboratory Developed Test (LDT) analyzed at the company's CAP-accredited, CLIA-certified laboratory. Healthcare providers submit patient samples for quantitative liver function assessment. Revenue is generated through test processing fees.
  2. Pharma Solutions / Clinical Trial Testing: Provides quantitative liver function testing services to pharmaceutical companies conducting clinical trials in liver disease. Includes support for Phase 2 and 3 drug trials, with HepQuant's tests used as endpoints for assessing treatment efficacy and patient stratification.
  3. Grant Funding: Received state-sponsored funding through Colorado Office of Economic Development and International Trade (OEDIT) Advanced Industry Accelerator Grant Program for supply chain development, regulatory advancements, and laboratory establishment.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goLaboratory Developed Test - No public pricing available

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

HepQuant product offering

Product offering

Core offering

HepQuant develops and provides noninvasive, blood-based quantitative liver function tests analyzed at its own CAP-accredited, CLIA-certified laboratory. Its core offerings are the FDA PMA-approved HepQuant SHUNT test for identifying patients with compensated cirrhosis unlikely to have large esophageal varices, and the HepQuant DuO Laboratory Developed Test that delivers a Disease Severity Index (DSI) along with portal-systemic shunting and hepatic reserve metrics. The company also supplies quantitative liver endpoints to pharmaceutical sponsors for use in liver disease clinical trials.

Product overview

HepQuant offers a portfolio of noninvasive, blood-based, quantitative liver function tests. The core offerings are the FDA-approved HepQuant SHUNT® Liver Diagnostic Test and the HepQuant DuO® Laboratory Developed Test (LDT). The SHUNT test received FDA premarket approval in June 2026 for identifying patients unlikely to have large esophageal varices, while the HepQuant DuO test provides broader liver health assessment including Disease Severity Index (DSI), SHUNT%, Hepatic Reserve (HR%), and Risk for Adverse Clinical Events (RISK ACE) metrics. The Pharma Solutions module extends these tests for use in pharmaceutical clinical trials, enabling drug developers to assess liver function and physiology across various liver disease presentations.

Differentiator

Problem solved

Functional benefit

Brands

  • HepQuant DuO: A noninvasive, blood-based quantitative test that measures liver function and portal circulation through a Disease Severity Index (DSI) score. It assesses critical liver cell processes and blood flow to the liver.
  • HepQuant SHUNT

Products and services

  • HepQuant SHUNT Liver Diagnostic Test FDA PMA-approved blood-based liver diagnostic test that generates a Disease Severity Index (DSI) score to identify adult patients with compensated cirrhosis (Child-Pugh Class A) unlikely to have large esophageal varices, potentially sparing them from endoscopy. It measures clearances of intravenously and orally administered cholate to assess liver function and portal-systemic shunting.
  • HepQuant DuO

Quantifiable outcome

  • 100% sensitivity and 100% negative predictive value for identifying patients unlikely to have large esophageal varices at DSI threshold of 18.3
  • +4 more outcomes

Companies that use HepQuant

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

HepQuant technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

HepQuant partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

HepQuant competitors and assessment

Company assessment

Broad incumbents

  • Labcorp: One of the largest US clinical reference laboratories operating CAP/CLIA labs nationwide with a broad hepatology and MASH testing menu. Relevant as both a potential commercial channel partner and a broad incumbent competing for clinical-trial central lab business against HepQuant's pharma services.
  • Siemens Healthineers: Offers the ADVIA Centaur ELF (Enhanced Liver Fibrosis) test on its clinical chemistry immunoassay platforms, a widely deployed noninvasive liver fibrosis assessment. Comparable as an incumbent blood-based liver fibrosis diagnostic competing for hepatology adoption.
  • Sonic Healthcare: Global clinical laboratory network with significant hepatology and gastroenterology testing services across the US, Europe, and Australia. Comparable as a broad incumbent that could partner with or compete against HepQuant for clinical-trial central lab and specialty liver testing volume.
  • Bio-Techne: Life-science tools and diagnostics company with proprietary biomarker assay content (including exosome-based and proteomic platforms) sold into pharma clinical trials and research labs. Comparable as a broader biomarker and clinical-trial assay supplier overlapping with HepQuant's pharma-services positioning.
  • Quest Diagnostics: Major US clinical reference laboratory with broad liver disease testing panels and clinical-trial central lab services. Comparable as a large incumbent serving hepatology providers and pharma sponsors across many of the same use cases HepQuant targets.

Direct peers

  • Genfit: Developer of NIS4, a blood-based MASH diagnostic biomarker test commercialized in the US through Labcorp. Targets the same hepatology/MASH patient stratification use case and pharma clinical-trial endpoint positioning as HepQuant.
  • Perspectum: Developer of LiverMultiScan, an MR-based quantitative liver diagnostic used for liver disease assessment and clinical-trial endpoints in MASH/NASH. Directly comparable to HepQuant as a quantitative, noninvasive liver diagnostic targeting hepatologists and pharma sponsors.
  • Echosens: Commercial-stage developer of FibroScan, the dominant noninvasive point-of-care liver elastography device used by hepatologists worldwide. Directly competes with HepQuant for the same hepatology customer segment seeking noninvasive liver disease assessment.

Others

  • Exact Sciences: Commercial-stage blood-based screening diagnostics company (Cologuard, Oncotype) with a large direct sales force targeting clinicians. Comparable as a US commercial-stage diagnostics platform whose playbook (CCO alumni at HepQuant helped build) and direct-to-physician model HepQuant is replicating for hepatology.

Emerging players

  • C2N Diagnostics: Privately held blood-based diagnostics company with proprietary mass-spec-based assays and a CLIA-certified lab, known for the PrecivityAD Alzheimer's test. Comparable as an emerging specialty blood-based diagnostics company with a CAP/CLIA lab and pharma-services exposure, though focused on neurology rather than hepatology.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

HepQuant social profiles

Digital presence

HepQuant compliance and trust

Trust signal

Compliance4 records

HepQuant financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HepQuant leadership team

Management profile

Number of profiles

Profiles13 records

HepQuant funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HepQuant M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HepQuant

What does HepQuant do?

HepQuant develops and provides noninvasive, blood-based quantitative liver function tests analyzed at its own CAP-accredited, CLIA-certified laboratory. Its core offerings are the FDA PMA-approved HepQuant SHUNT test for identifying patients with compensated cirrhosis unlikely to have large esophageal varices, and the HepQuant DuO Laboratory Developed Test that delivers a Disease Severity Index (DSI) along with portal-systemic shunting and hepatic reserve metrics. The company also supplies quantitative liver endpoints to pharmaceutical sponsors for use in liver disease clinical trials.

Is HepQuant a public or private company?

HepQuant is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was HepQuant founded?

HepQuant was founded in 2007. It employs 11 to 50 people.

Where is HepQuant based?

HepQuant is headquartered in Denver, United States, in the North America region.

How does HepQuant make money?

Three revenue lines are on record. Clinical Diagnostic Testing Services are the primary driver. The others are pharma Solutions / Clinical Trial Testing and grant Funding.

Who are HepQuant's main competitors?

Broad incumbents on record are Labcorp, Siemens Healthineers, Sonic Healthcare, Bio-Techne and Quest Diagnostics. Direct peers are Genfit, Perspectum and Echosens. Exact Sciences is listed as an others. C2N Diagnostics is listed as an emerging player.

Does HepQuant have an API?

No public API is recorded for HepQuant.

What industry is HepQuant in?

HepQuant's product category is Liver Disease Diagnostics. Its primary akta.pro industry code is HLAKAEAB, Hepatology & Liver Disease, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageHepQuant to Present Five Abstracts at AASLD’s The Liver Meeting® 2026HepQuant will present five abstracts at AASLD's The Liver Meeting 2026 in Denver, November 5-9. The studies focus on the HepQuant DuO test's Disease Severity Index, including analyses of 643, 1,266, and 215 participants, and findings from 14 clinical trials. The company says the test may help identify patients at risk of decompensation and serve as a quantitative endpoint for trials.Business Wire BlogHepQuant to Present Five Abstracts at AASLD’s The Liver Meeting® 2026HepQuant will present five abstracts at AASLD's The Liver Meeting 2026 in Denver, November 5-9. The studies focus on the HepQuant DuO test's Disease Severity Index, with analyses of 643 participants, 1,266 participants, and 14 clinical trials. The company says the test may help identify patients at risk of portal hypertension and decompensation.BioSpaceFDA Approves the HepQuant SHUNT® Liver Diagnostic Test to Quantify Risk of Large Esophageal Varices in Adult Patients with Compensated Cirrhosis (Child Pugh Class A)The FDA granted premarket approval to HepQuant's SHUNT Liver Diagnostic Test for quantifying risk of large esophageal varices in compensated cirrhosis. A DSI score below 18.3 identifies patients unlikely to have large varices, with 100% sensitivity and negative predictive value in the SHUNT-V study.In VivoHepQuant SHUNT Wins FDA Premarket Approval For Variceal Screening In Compensated CirrhosisThe FDA granted premarket approval to HepQuant SHUNT, a blood-based liver function test that quantifies the risk of large esophageal varices in adult patients with compensated cirrhosis (Child-Pugh Class A). The test generates a Disease Severity Index score from cholate clearance measurements, with a score below 18.3 identifying patients unlikely to have large varices who may safely avoid endoscopy. The approval represents one of the first FDA-authorized diagnostics to use a quantitative measure of liver function, potentially reducing unnecessary endoscopic procedures.Business Wire BlogFDA Approves the HepQuant SHUNT® Liver Diagnostic Test to Quantify Risk of Large Esophageal Varices in Adult Patients with Compensated Cirrhosis (Child Pugh Class A)The FDA granted premarket approval (PMA) for the HepQuant SHUNT® Liver Diagnostic Test, which generates a Disease Severity Index (DSI) score to identify patients with compensated cirrhosis (Child Pugh Class A) unlikely to have large esophageal varices. The test demonstrated 100% sensitivity and 100% negative predictive value in a prospective multicenter US clinical study involving 195 subjects. HepQuant, a privately held diagnostics company based in Denver, Colorado, developed the test to improve clinical management of chronic liver disease, which causes over 52,000 deaths annually in the United States.FinancialContent Business PageFDA Approves the HepQuant SHUNT® Liver Diagnostic Test to Quantify Risk of Large Esophageal Varices in Adult Patients with Compensated Cirrhosis (Child Pugh Class A)The FDA granted premarket approval (PMA) for the HepQuant SHUNT® Liver Diagnostic Test, a blood-based diagnostic that generates a Disease Severity Index score to identify patients with compensated cirrhosis (Child Pugh Class A) unlikely to have large esophageal varices, potentially sparing them from endoscopy. The pivotal SHUNT-V clinical study demonstrated 100% sensitivity and 100% negative predictive value at the DSI threshold of 18.3 in 195 evaluable subjects. HepQuant, a privately held diagnostics company based in Denver, Colorado, developed the test to address the clinical and economic burden of chronic liver disease, which causes over 52,000 deaths annually in the US and affects 112 million people worldwide with compensated cirrhosis.PrwebHepQuant Achieves College of American Pathologists (CAP) Accreditation Demonstrating Commitment to Laboratory ExcellenceHepQuant announced that its laboratory has achieved accreditation from the College of American Pathologists (CAP), a gold-standard certification in clinical laboratory medicine. The accreditation recognizes HepQuant's commitment to quality, accuracy, and compliance in laboratory operations. CAP accreditation is widely recognized by hospitals and healthcare institutions as a rigorous benchmark for high-quality laboratory services and patient care.PrwebThree Presentations at EASL 2026 Highlight the Clinical and Drug Development Value of HepQuant DuO®HepQuant, LLC announced the presentation of three studies at the 2026 Congress of the European Association for the Study of the Liver, showcasing the clinical and research value of its HepQuant DuO® test and Disease Severity Index. The studies demonstrated the test's utility in quantifying liver health, optimizing clinical trial design for compensated MASH, stratifying hepatotoxicity risk in cirrhosis patients undergoing radiologic therapy, and detecting early changes in liver function during antiviral treatment. The company's CEO highlighted that direct measurement of liver function provides insights relevant to both clinical care and drug development.Prweb2026 DDW Oral Presentation: HepQuant DuO® Disease Severity Index (DSI) Outperforms Child-Pugh and MELD Scores in Predicting Risk of Esophageal VaricesHepQuant announced at Digestive Disease Week 2026 that its DuO Disease Severity Index (DSI) was a significant predictor of esophageal varices risk, while Child-Pugh and MELD scores were not, based on data from two US prospective studies (SHUNT-V, n=238; HALT-C, n=216). The findings support HepQuant DuO's clinical utility in managing compensated advanced chronic liver disease, specifically for decisions regarding endoscopy use and patient follow-up intensity.PrwebHepQuant Presents Exciting Abstracts at The Liver Meeting 2025 Demonstrating HepQuant DuO® Utility to Uncover Functional and Physiological HeterogeneityHepQuant presented three abstracts at The Liver Meeting 2025 conference demonstrating the utility of its HepQuant DuO non-invasive blood test for assessing liver health. The test measures liver cell processes and blood flow to evaluate disease severity, progression, and improvement in patients with advanced MASH and chronic HCV. One abstract focused on measuring functional recovery in living donors who underwent right lobectomy.